TY  - JOUR
AU  - de Marinis, Filippo
AU  - Ciardiello, Fortunato
AU  - Baas, Paul
AU  - Crinò, Lucio
AU  - Giaccone, Giuseppe
AU  - Grossi, Francesco
AU  - Hellmann, Matthew D
AU  - Mok, Tony S K
AU  - Lena, Hervè
AU  - Paz-Ares, Luis
AU  - Rodriguez-Abreu, Delvys
AU  - Von Pavel, Joachim
AU  - Gridelli, Cesare
PY  - 2018
DO  - 10.1136/esmoopen-2017-000298
SN  - 2059-7029
UR  - https://hdl.handle.net/10668/25593
T2  - ESMO open
AB  - Although lung cancer remains the leading cause of death from cancer worldwide, the advent of immunotherapy is changing the survival of patients affected by non-small cell lung cancer (NSCLC). A multitude of clinical trials are evaluating different...
LA  - en
KW  - NSCLC
KW  - algorithm
KW  - atezolizumab
KW  - immunotherapy
KW  - nivolumab
KW  - pembrolizumab
TI  - 30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT).
TY  - research article
VL  - 3
ER  -